CliffBio
biologic

Mylotarg

gemtuzumab ozogamicin

Loss of exclusivity—loss of exclusivity
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameMylotarg
Active ingredientgemtuzumab ozogamicin
Strength4.5MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.